Atreca (BCEL) Prices 7.031 Class A Share Common Offering at $16/Sh

Atreca, Inc. (NASDAQ: BCEL), a biopharmaceutical company utilizing its differentiated platform to discover and develop novel antibody-based immunotherapeutics to treat a range of solid tumor types, today announced the pricing of its previously announced underwritten public offering of 7,031,250 shares of its Class A Common Stock and 781,250 shares of its Class B Common Stock (the “Shares”), each at a price to the public of $16.00 per share. Gross proceeds to Atreca from the offering are expected to be $125.0 million, before deducting underwriting discounts and commissions and estimated offering expenses. In addition, Atreca has granted the underwriters a 30-day option to purchase up to 1,171,875 additional shares of its Class A Common Stock at the public offering price, less underwriting discounts and commissions. The offering is expected to close on or about July 20, 2020, subject to the satisfaction of customary closing conditions. All of the shares are being offered by Atreca.

Cowen and Company, LLC, Evercore Group L.L.C. and Stifel, Nicolaus & Company, Incorporated are acting as joint book-running managers for the offering. Canaccord Genuity LLC is acting as lead manager for the offering. Roth Capital Partners, LLC and Brookline Capital Markets, a division of Arcadia Securities, LLC are acting as co-managers for the offering.

A shelf registration statement relating to the offered Shares was filed with the Securities and Exchange Commission (SEC) on July 2, 2020, and was declared effective on July 10, 2020.

You May Also Be Interested In

• SEC plans crypto investment regime and tokenized stock exemption - Bloomberg
• AbCellera launches $200M public offering of common stock
• American Ocean Minerals names Paul Warmé as CFO